| Entry |
|
|---|
| Name |
Procainamide (INN) |
|---|
| Formula |
C13H21N3O
|
|---|
| Exact mass |
235.1685
|
|---|
| Mol weight |
235.3253
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01653 Antiarrhythmics
DG01652 Class I antiarrhythmic agent
DG01649 Class Ia antiarrhythmic agent
Metabolizing enzyme substrate
DG02928 NAT substrate
Transporter substrate
DG02858 SLC22A1 substrate
DG02854 SLC22A2 substrate
DG02964 SLC47A1 substrate
DG03002 SLC47A2 substrate
|
|---|
| Remark |
| Product (DG00193): | D00477<JP/US> |
|
|---|
| Efficacy |
Antiarrhythmic, Sodium channel blocker |
|---|
| Target |
|
|---|
| Pathway |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
|
|---|
| Metabolism |
Enzyme: NAT [HSA: 9 10]
Transporter: SLC22A1 [HSA: 6580], SLC22A2 [HSA: 6582], SLC47A1 [HSA: 55244], SLC47A2 [HSA: 146802]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07213 | Dopamine receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01B ANTIARRHYTHMICS, CLASS I AND III
C01BA Antiarrhythmics, class Ia
C01BA02 Procainamide
D08421 Procainamide (INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01653 Antiarrhythmics
DG01652 Class I antiarrhythmic agent
DG01649 Class Ia antiarrhythmic agent
DG00193 Procainamide
D08421 Procainamide
Metabolizing enzyme substrate
DG02928 NAT substrate
DG00193 Procainamide
D08421 Procainamide
Transporter substrate
DG02858 SLC22A1 substrate
DG00193 Procainamide
D08421 Procainamide
DG02854 SLC22A2 substrate
DG00193 Procainamide
D08421 Procainamide
DG02964 SLC47A1 substrate
DG00193 Procainamide
D08421 Procainamide
DG03002 SLC47A2 substrate
DG00193 Procainamide
D08421 Procainamide
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN1A
D08421 Procainamide (INN)
SCN2A
D08421 Procainamide (INN)
SCN3A
D08421 Procainamide (INN)
SCN4A
D08421 Procainamide (INN)
SCN5A
D08421 Procainamide (INN)
SCN8A
D08421 Procainamide (INN)
SCN9A
D08421 Procainamide (INN)
SCN10A
D08421 Procainamide (INN)
SCN11A
D08421 Procainamide (INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08421
Drug transporters
D08421
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D08421
Drug groups [BR:br08330]
Cardiovascular agent
DG01653 Antiarrhythmics
DG01652 Class I antiarrhythmic agent
DG01649 Class Ia antiarrhythmic agent
DG00193 Procainamide
Metabolizing enzyme substrate
DG02928 NAT substrate
DG00193 Procainamide
Transporter substrate
DG02858 SLC22A1 substrate
DG00193 Procainamide
DG02854 SLC22A2 substrate
DG00193 Procainamide
DG02964 SLC47A1 substrate
DG00193 Procainamide
DG03002 SLC47A2 substrate
DG00193 Procainamide
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 17
1 C8y C 16.1435 -15.8683
2 C5a C 17.4720 -16.5674
3 C8x C 16.1436 -14.4001
4 C8x C 15.0250 -16.4975
5 N1b N 18.6605 -15.8683
6 O5a O 17.4721 -17.9656
7 C8x C 15.0250 -13.7010
8 C8x C 13.7665 -15.7983
9 C1b C 19.8490 -16.5674
10 C8y C 13.7664 -14.4001
11 C1b C 21.1074 -15.8683
12 N1a N 12.5780 -13.7010
13 N1c N 22.2960 -16.5674
14 C1b C 23.4845 -15.8683
15 C1b C 22.2960 -17.9656
16 C1a C 24.7430 -16.5674
17 C1a C 23.4845 -18.6648
BOND 17
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 2 6 2
6 3 7 1
7 4 8 2
8 5 9 1
9 7 10 2
10 9 11 1
11 10 12 1
12 11 13 1
13 13 14 1
14 13 15 1
15 14 16 1
16 15 17 1
17 8 10 1
|
|---|
